Citius
CTXR
Citius (CTXR) news
Recent news
Addi reports $85M Series D led by Citius
AInvest Wire · Jul 1, 2026ImportantCitius Pharmaceuticals achieves primary & secondary endpoints.
Citius Pharmaceuticals achieves primary & secondary endpoints. Citius Pharmaceuticals, a specialty pharmaceutical company, recently reported the successful achievement of primary and secondary endpoints in a clinical study for its lead product, Minosan-Na (minocycline). The trial, which enrolled…
AInvest Wire · May 21, 2024ImportantCitius to merge unit with Tenx to form Citius Oncology; Citius to receive $675M in equity
AInvest Wire · Oct 24, 2023Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.